Kronos Bio, Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a KRON research report →
Companykronosbio.com
Kronos Bio, Inc. , a clinical-stage biopharmaceutical company, focuses on the discovery and development of novel cancer therapeutics. The company's product engine focuses on dysregulated transcription factors and the transcriptional regulatory networks that drive oncogenic activity.
- CEO
- Deborah A. Knobelman
- IPO
- 2020
- Employees
- 8
- HQ
- San Mateo, CA, US
Price Chart
Valuation
- Market Cap
- $53.65M
- P/E
- -1.57
- P/S
- 12.98
- P/B
- 0.67
- EV/EBITDA
- 0.82
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 91.58%
- Op Margin
- -885.24%
- Net Margin
- -826.73%
- ROE
- -40.83%
- ROIC
- -35.22%
Growth & Income
- Revenue
- $9.85M · 56.62%
- Net Income
- $-86,079,000 · 23.60%
- EPS
- $-1.43 · 26.67%
- Op Income
- $-92,887,000
- FCF YoY
- 17.44%
Performance & Tape
- 52W High
- $1.46
- 52W Low
- $0.65
- 50D MA
- $0.80
- 200D MA
- $0.90
- Beta
- 1.64
- Avg Volume
- 855.96K
Get TickerSpark's AI analysis on KRON
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jun 20, 25 | Belldegrun Arie | sell | 34,000 |
| Jun 20, 25 | Belldegrun Arie | sell | 20,600 |
| Jun 20, 25 | Belldegrun Arie | other | 679,575 |
| Jun 20, 25 | Belldegrun Arie | sell | 34,000 |
| Jun 20, 25 | Belldegrun Arie | sell | 34,000 |
| Jun 20, 25 | BISCHOFBERGER NORBERT W | other | 263,750 |
| Jun 20, 25 | BISCHOFBERGER NORBERT W | sell | 297,186 |
| Jun 20, 25 | BISCHOFBERGER NORBERT W | sell | 400,000 |
| Jun 20, 25 | BISCHOFBERGER NORBERT W | sell | 570,868 |
| Jun 20, 25 | BISCHOFBERGER NORBERT W | sell | 699,800 |
Our KRON Coverage
We haven't published any research on KRON yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate KRON Report →